about
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's diseaseDual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusionCurcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st centurySRp54 (SFRS11), a regulator for tau exon 10 alternative splicing identified by an expression cloning strategyTemperature and toxic Tau in Alzheimer's disease: new insightsNew Features about Tau Function and DysfunctionNeurodegeneration and microtubule dynamics: death by a thousand cutsGenetics of Progressive Supranuclear PalsyMouse models of frontotemporal dementiaSuccessful therapies for Alzheimer's disease: why so many in animal models and none in humans?Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targetsTangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing ProblemThe role of tau in neurodegenerative diseases and its potential as a therapeutic targetClosing the tau loop: the missing tau mutation.Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD.Astrocytes: biology and pathologyTargeting mRNA for Alzheimer's and related dementias.The struggle by Caenorhabditis elegans to maintain proteostasis during aging and diseaseTau StructuresSaitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6The effect of a DeltaK280 mutation on the unfolded state of a microtubule-binding repeat in TauMultiple-motor based transport and its regulation by Tau.Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic lossPhosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport.Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment.Roles of tau protein in health and disease.Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome miceInhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 miceAlzheimer's disease: insights from Drosophila melanogaster models.Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.Targeting Abeta and tau in Alzheimer's disease, an early interim reportTau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding.Evaluation of autophagy using mouse models of brain injury.Genetics and biology of Alzheimer's disease and frontotemporal lobar degenerationHeat shock protein 90 in neurodegenerative diseasesThe intersection of amyloid beta and tau at synapses in Alzheimer's diseaseDevelopment of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathiesTau binds to lipid membrane surfaces via short amphipathic helices located in its microtubule-binding repeatsClinical phenotypes and genetic biomarkers of FTLD.Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice.
P2860
Q24302457-AE40CB87-9BC2-4D7D-97BA-8B43F43377A3Q24339549-4EC97B3D-C184-40AF-875F-02BC4A9A1C20Q24630927-9EB179CA-7BF5-4AD9-8E0F-E528857909EFQ24670290-3F77687F-9176-4481-81F4-4EC3C5C6A896Q26745778-854E9C91-D3F0-46E5-B66E-D8BB5604D9B6Q26750922-5A87ECF6-A166-474F-80AF-47B190ADFB59Q26781649-3D7629A9-9354-4FEA-BD08-D9C662EE4733Q26785904-95BFE1D1-D579-4D06-BA5C-5711984C6A70Q26829009-3D3D0810-B329-49E3-9E26-DF82CD8951FDQ26859305-3FE91E10-A8F8-4E1C-9734-BC72B9918CD1Q26865654-358D33A0-1E66-4D44-91F2-89D583C8EE22Q27004724-D906F2E2-2FA5-4094-9743-2C3FB392FC96Q27005032-4180F952-231F-4884-966D-1D15CB05DCA1Q27303641-B081046A-2FE8-422A-BFBF-3202DAB88838Q27317039-FACFF780-3BE9-4C72-AFC0-BB1424FF9CBCQ27490746-424ADE3E-A835-4D21-8EBC-A17FB35287FCQ27687153-1A6402E6-EF6D-4E2D-9FC5-10196FEBD6D7Q28069294-887221D6-CCD7-4A1C-A511-E5C4DBFE9395Q28076921-A6372B40-E952-4731-8D0C-4E9735763C30Q28274071-843E462C-75DB-4F91-BC9F-3313BF1AF172Q28473391-44611426-C652-4E0C-95BF-7C41F027331CQ30478710-4B3E31F8-DB52-44E2-B7E2-E74226A27998Q30497471-C98BF7D0-89D0-47EF-9B7E-B4E20EF0ED4EQ30504709-20398493-F67D-4182-A8E8-39E5DECA3429Q33559266-E8999E0A-E4C9-4AF6-8F93-B129A329A48FQ33559303-725E2ED3-F30B-4590-B3DE-99F16C944075Q33674369-ADD05193-C47F-4D66-9741-0F83953D7F86Q33706940-97C8375A-3828-4E6E-A637-93C75C19B606Q33799241-7831F097-DD5A-4B21-BDD8-17CF9489548EQ33828966-3901BCED-9551-4E98-A7D7-45FFD2F21066Q33829008-09E13DAF-2D19-4FB0-9598-124EE5A05CBDQ33911246-006D31F0-76AB-42F7-85CD-A5120FB777D3Q33937774-A9063C6A-F741-4290-BC52-ACE308250D33Q33951192-8CFF7A2D-CF32-4330-B4BA-E2A5FD9B4D94Q33961301-8210B222-660F-4CB0-B5E0-6F8861DCEABDQ34054680-D657BB88-47F4-48EB-B0D2-6229EE4AB138Q34154643-14739069-09C8-4935-BF5C-A1CF85A7D146Q34203739-1293EFAC-3A91-4201-8EEC-1C3CBFD5AA5AQ34243054-572F5F60-62EA-4060-B456-D7A2D634D8AAQ34541965-23F3AA85-EF13-4221-A51B-172D258499FF
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Mutations causing neurodegenerative tauopathies.
@ast
Mutations causing neurodegenerative tauopathies.
@en
type
label
Mutations causing neurodegenerative tauopathies.
@ast
Mutations causing neurodegenerative tauopathies.
@en
prefLabel
Mutations causing neurodegenerative tauopathies.
@ast
Mutations causing neurodegenerative tauopathies.
@en
P1476
Mutations causing neurodegenerative tauopathies.
@en
P2093
Michel Goedert
Ross Jakes
P304
P356
10.1016/J.BBADIS.2004.08.007
P407
P577
2005-01-01T00:00:00Z